Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022
September 14 2022 - 10:00AM
Business Wire
Pfizer Inc. (NYSE: PFE) invites investors and the general public
to view and listen to a webcast of a conference call with
investment analysts at 4:30 p.m. EDT on Wednesday, September 21,
2022. Pfizer Internal Medicine leadership will review the oral
GLP-1 data presented at the European Association for the Study of
Diabetes (EASD) 2022.
To view and listen to the webcast, visit our web site at
www.pfizer.com/investors. Information on accessing and registering
for the webcast will be available at www.pfizer.com/investors
beginning today. Participants are advised to register in advance of
the conference call.
You can also listen to the conference call by dialing either
800-456-4352 in the United States and Canada or 785-424-1086
outside of the United States and Canada. The passcode is
“70409”.
The transcript and webcast replay of the discussion will be made
available on our web site at www.pfizer.com/investors within 24
hours after the end of the live discussion and will be accessible
for at least 90 days.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The webcast may include
forward-looking statements about, among other things, Pfizer’s oral
GLP-1 candidate, including anticipated regulatory submissions, data
read-outs, study starts, approvals, clinical trial results and
other developing data, revenue contribution, growth, performance,
timing of exclusivity and potential benefits, that are subject to
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. A description of these risks and uncertainties can be
found in Pfizer’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2021 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of
the original date of the webcast. Pfizer assumes no obligation to
update forward-looking statements contained in the webcast as the
result of new information or future events or developments.
Category: Finance
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220914005045/en/
Media PfizerMediaRelations@Pfizer.com +1 (212) 733-1226
Investor IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024